San Diego, CA, May 17, 2017: Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloid-related disorders such as Alzheimer’s disease, announced the addition of Scott A. Reines, M.D., Ph.D. to their executive team. Dr. Reines will serve as Chief Medical Officer and work alongside Dr. Richard D’Souza in driving the R&D platform through clinical trials.
“Amydis is fortunate to have Scott join our executive team. Dr. Reines has a unique blend of experience in neurology and ophthalmology and developing innovative branded products that make him an ideal fit for the Company,” said Stella Sarraf, Ph.D., Interim Chief Executive Officer and Founder of Amydis Diagnostics, Inc. “Dr. Reines will lead the clinical development of our lead program in Alzheimer’s as well as help build our pipeline”.
“I have had the pleasure of working with Scott when I was at Merck and am excited to be teamed up with him again,” said Franz Hefti, Ph.D., Board Member of Amydis. “He is a fantastic addition to the Amydis team.”
Dr. Reines is a research physician with broad drug development experience leading to the approval of new drugs in five different therapeutic areas including neurology and ophthalmology. Prior to Amydis, he has served in leading roles at Johnson & Johnson and Merck, and currently chairs a Data Safety Monitoring Board. As Senior Vice President for CNS, Pain and Translational Medicine at J&J, Dr. Reines oversaw the development and approval of numerous drugs for the treatment of schizophrenia, Alzheimer’s, pain and migraine headache. Prior to that, Dr. Reines served as Vice President, Clinical Research at Merck with responsibilities for Psychopharmacology, Neuropharmacology, Gastroenterology, and Ophthalmology. While there, he oversaw the conduct on one of the first large, multicenter trials for the prevention of Alzheimer’s disease and led the development of leading brand drugs for nausea and vomiting, migraine, Parkinson’s and glaucoma.
Dr. Reines served for two years as co-chair of the Neuroscience Steering Committee, Foundation for NIH Biomarkers Consortium, and spent five years on the National Drug Abuse Advisory Council. He is currently Vice Chair of the Board of Directors of KidsPeace, a national children’s psychiatric and behavioral healthcare provider He holds a bachelor’s degree in chemistry from Cornell University, a doctoral degree in chemistry/molecular biology from Columbia University, and a medical degree from Albert Einstein College of Medicine. He is Board Certified in Psychiatry and Neurology.
Amydis Diagnostics, Inc. was founded in 2013 to address the urgent medical and clinical need for more sensitive and specific diagnostic testing for Alzheimer’s disease. By significantly improving the effectiveness, accessibility, and ease of testing, our unique technology has the potential to help physicians detect Alzheimer’s disease at its earliest stages, and in doing so, allows appropriate therapeutic options to be developed or pursued. The power of knowing will enable patients and physicians to make the right decisions and change the lives of those impacted by the disease. More information on Amydis can be found at www.amydis.com.
This news release contains "forward-looking statements" concerning the development and commercialization of Amydis’ pipeline products, the potential benefits and attributes of such products, and the Company's expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this news release. Actual results may vary. Amydis undertakes no obligation to update any forward-looking statements for any reason.
Amydis Diagnostics Contact
David H. Crean, Ph.D.
Chief Business Officer
Amydis Diagnostics, Inc.
3210 Merryfield Row San Diego, CA 92121
Amydis Diagnostics Awarded NIH Grant to Further Investigate Innovative Technology for Early Detection of Alzheimer’s DiseaseSan Diego, CA, March 19, 2017: Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloid-related neurodegenerative disorders such as Alzheimer’s disease, announced that they received a Phase 2 SBIR grant award by the National Institute on Aging (NIA) of the National Institutes of Health (NIH). The grant award for $1.8 million will fund research and development of a novel ophthalmic diagnostic probe for Alzheimer’s Disease. The company previously was awarded a Phase 1 grant from 2015-2016.
Alzheimer’s disease is a significant healthcare burden and unmet medical need. Buildup and deposition of amyloid-beta plaques in the brain is a hallmark of the disease, and this accumulation continues to be the leading biomarker of interest for early detection. Accrual of amyloid-beta is believed to typically occur well before the appearance of clinical symptoms of cognitive decline.
The ability to identify amyloid-beta deposits helps in identifying patients at risk for Alzheimer’s disease and enables enrollment of patients in clinical trials investigating disease modifying treatments, and may ultimately guide therapeutic intervention at an early stage. Current diagnostic procedures to detect amyloid-beta in the brain are based on brain imaging techniques or biochemical assays following an invasive procedure. Amydis aims at establishing less costly, non-invasive diagnostic procedures based on ophthalmologic procedures.
“Amydis is fortunate to have been selected for this highly competitive grant award. The award reflects NIA's commitment to finding truly novel approaches to detecting and treating Alzheimer's disease,” said Stella Sarraf, Ph.D., Interim Chief Executive Officer and Founder of Amydis Diagnostics, Inc. “This grant provides rigorous peer-reviewed validation of the opportunity approach we've taken to the development of our technology and allows us to further develop and take our promising technology to the marketplace for the detection of amyloid-beta deposits as a diagnostic for Alzheimer’s disease".
About Amydis Diagnostics
Amydis Diagnostics, Inc. was founded in 2013 to address the urgent medical and clinical need for more sensitive and specific diagnostic testing for Alzheimer’s disease. By significantly improving the effectiveness, accessibility, and ease of testing, our unique technology has the potential to help physicians detect Alzheimer’s disease at its earliest stages. The power of knowing will enable patients and physicians to make the right decisions and change the lives of those impacted by the disease.